<meta http-equiv="Content-Type" content="text/html; charset=utf-8"><link type="text/css" rel="stylesheet" href="resources/sheet.css" >
<style type="text/css">.ritz .waffle a { color: inherit; }.ritz .waffle .s0{background-color:#ffffff;text-align:left;color:#000000;font-family:Arial;font-size:10pt;vertical-align:bottom;white-space:nowrap;direction:ltr;padding:2px 3px 2px 3px;}.ritz .waffle .s1{border-right:none;background-color:#ffffff;text-align:left;color:#000000;font-family:Arial;font-size:10pt;vertical-align:bottom;white-space:nowrap;direction:ltr;padding:2px 3px 2px 3px;}</style><div class="ritz grid-container" dir="ltr"><table class="waffle" cellspacing="0" cellpadding="0"><thead><tr><th class="row-header freezebar-origin-ltr"></th><th id="955405797C0" style="width:100px;" class="column-headers-background">A</th><th id="955405797C1" style="width:100px;" class="column-headers-background">B</th><th id="955405797C2" style="width:100px;" class="column-headers-background">C</th><th id="955405797C3" style="width:100px;" class="column-headers-background">D</th><th id="955405797C4" style="width:100px;" class="column-headers-background">E</th><th id="955405797C5" style="width:100px;" class="column-headers-background">F</th></tr></thead><tbody><tr style="height: 20px"><th id="955405797R0" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">1</div></th><td class="s0">Theme</td><td class="s0">Time</td><td class="s0">Venue</td><td class="s0">Speaker</td><td class="s0">Session</td><td class="s0">Session Time</td></tr><tr style="height: 20px"><th id="955405797R1" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">2</div></th><td class="s0 softmerge"><div class="softmerge-inner" style="width:97px;left:-1px">Opening Session</div></td><td class="s0">08:00–08:25</td><td class="s0">Grand Ballroom</td><td class="s0 softmerge"><div class="softmerge-inner" style="width:97px;left:-1px">Malvina EYDELMAN (U.S.)</div></td><td class="s0">08:00–08:05</td><td class="s1 softmerge"><div class="softmerge-inner" style="width:198px;left:-1px">Welcome Remarks</div></td></tr><tr style="height: 20px"><th id="955405797R2" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">3</div></th><td class="s0"></td><td class="s0"></td><td class="s0"></td><td class="s0 softmerge"><div class="softmerge-inner" style="width:97px;left:-1px">Dennis LAM (Hong Kong)</div></td><td class="s0">08:05–08:25</td><td class="s1 softmerge"><div class="softmerge-inner" style="width:298px;left:-1px">Keynote Lecture 1: Myopia Management in Asia</div></td></tr><tr style="height: 20px"><th id="955405797R3" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">4</div></th><td class="s0 softmerge"><div class="softmerge-inner" style="width:97px;left:-1px">Session 1: Key Parameters for Effective Myopia Control Products</div></td><td class="s0">08:30–09:45</td><td class="s0">Grand Ballroom</td><td class="s0 softmerge"><div class="softmerge-inner" style="width:97px;left:-1px">Daniel TING (Singapore)</div></td><td class="s0">08:30–08:38</td><td class="s1 softmerge"><div class="softmerge-inner" style="width:298px;left:-1px">Summary of CCOI’s Myopia Workshop</div></td></tr><tr style="height: 20px"><th id="955405797R4" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">5</div></th><td class="s0"></td><td class="s0"></td><td class="s0"></td><td class="s0 softmerge"><div class="softmerge-inner" style="width:97px;left:-1px">Gareth LINGHAM / David MACKEY</div></td><td class="s0">08:38–08:46</td><td class="s1 softmerge"><div class="softmerge-inner" style="width:498px;left:-1px">Axial Length Progression is preferred – How much benefit should there be?</div></td></tr><tr style="height: 20px"><th id="955405797R5" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">6</div></th><td class="s0"></td><td class="s0"></td><td class="s0"></td><td class="s0 softmerge"><div class="softmerge-inner" style="width:97px;left:-1px">Chris HAMMOND (U.K.)</div></td><td class="s0">08:46–08:54</td><td class="s1 softmerge"><div class="softmerge-inner" style="width:498px;left:-1px">Spherical Equivalent is preferred – How much benefit should there be?</div></td></tr><tr style="height: 20px"><th id="955405797R6" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">7</div></th><td class="s0"></td><td class="s0"></td><td class="s0"></td><td class="s0 softmerge"><div class="softmerge-inner" style="width:97px;left:-1px">Donald MUTTI (U.S.)</div></td><td class="s0">08:54–09:02</td><td class="s1 softmerge"><div class="softmerge-inner" style="width:498px;left:-1px">Are There Alternatives to a Placebo Control Group That Are Acceptable?</div></td></tr><tr style="height: 20px"><th id="955405797R7" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">8</div></th><td class="s0"></td><td class="s0"></td><td class="s0"></td><td class="s0 softmerge"><div class="softmerge-inner" style="width:97px;left:-1px">Wesley BEAULIEU (U.S.)</div></td><td class="s0">09:02–09:10</td><td class="s1 softmerge"><div class="softmerge-inner" style="width:198px;left:-1px">Fast Progressors – Fact or Myth</div></td></tr><tr style="height: 20px"><th id="955405797R8" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">9</div></th><td class="s0"></td><td class="s0"></td><td class="s0"></td><td class="s0 softmerge"><div class="softmerge-inner" style="width:97px;left:-1px">ATLAS Team / Donald MUTTI / Donald TAN</div></td><td class="s0">09:10–09:18</td><td class="s1 softmerge"><div class="softmerge-inner" style="width:498px;left:-1px">Long-Term Follow-up of Effectiveness – What Are Acceptable Alternatives?</div></td></tr><tr style="height: 20px"><th id="955405797R9" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">10</div></th><td class="s0"></td><td class="s0"></td><td class="s0"></td><td class="s0 softmerge"><div class="softmerge-inner" style="width:97px;left:-1px">Moderators &amp; Panelists</div></td><td class="s0">09:18–09:45</td><td class="s1 softmerge"><div class="softmerge-inner" style="width:198px;left:-1px">Panel Discussion</div></td></tr><tr style="height: 20px"><th id="955405797R10" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">11</div></th><td class="s0 softmerge"><div class="softmerge-inner" style="width:97px;left:-1px">Session 2: Lens Power – Shaping the Future</div></td><td class="s0">10:15–11:10</td><td class="s0">Grand Ballroom</td><td class="s0 softmerge"><div class="softmerge-inner" style="width:97px;left:-1px">Olga PRENAT (France)</div></td><td class="s0">10:15–10:23</td><td class="s1 softmerge"><div class="softmerge-inner" style="width:498px;left:-1px">From Prevention to Progression Management with Spectacle Solutions</div></td></tr><tr style="height: 20px"><th id="955405797R11" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">12</div></th><td class="s0"></td><td class="s0"></td><td class="s0"></td><td class="s0 softmerge"><div class="softmerge-inner" style="width:97px;left:-1px">Eddie CATALFAMO (U.S.)</div></td><td class="s0">10:23–10:31</td><td class="s1 softmerge"><div class="softmerge-inner" style="width:398px;left:-1px">Reimagining Myopia Control: Next-Gen Contact Lens Technology</div></td></tr><tr style="height: 20px"><th id="955405797R12" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">13</div></th><td class="s0"></td><td class="s0"></td><td class="s0"></td><td class="s0 softmerge"><div class="softmerge-inner" style="width:97px;left:-1px">Li Lian FOO (Singapore) / Pauline CHO</div></td><td class="s0">10:31–10:39</td><td class="s0">Contact Lenses</td></tr><tr style="height: 20px"><th id="955405797R13" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">14</div></th><td class="s0"></td><td class="s0"></td><td class="s0"></td><td class="s0 softmerge"><div class="softmerge-inner" style="width:97px;left:-1px">Moderators &amp; Panelists</div></td><td class="s0">10:39–11:10</td><td class="s1 softmerge"><div class="softmerge-inner" style="width:198px;left:-1px">Panel Discussion</div></td></tr><tr style="height: 20px"><th id="955405797R14" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">15</div></th><td class="s0 softmerge"><div class="softmerge-inner" style="width:97px;left:-1px">Session 3: Pharmacologic Frontiers – Targeting Myopia</div></td><td class="s0">11:10–12:25</td><td class="s0">Grand Ballroom</td><td class="s0 softmerge"><div class="softmerge-inner" style="width:97px;left:-1px">Lavin ACHUDAN (Singapore)</div></td><td class="s0">11:10–11:18</td><td class="s1 softmerge"><div class="softmerge-inner" style="width:498px;left:-1px">Halting the Myopia Tsunami in Asia: The Role of Early Low-Dose Atropine</div></td></tr><tr style="height: 20px"><th id="955405797R15" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">16</div></th><td class="s0"></td><td class="s0"></td><td class="s0"></td><td class="s0">Donald TAN</td><td class="s0">11:18–11:26</td><td class="s1 softmerge"><div class="softmerge-inner" style="width:398px;left:-1px">Atropine Concentration: Lessons from the ATOM Studies</div></td></tr><tr style="height: 20px"><th id="955405797R16" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">17</div></th><td class="s0"></td><td class="s0"></td><td class="s0"></td><td class="s0 softmerge"><div class="softmerge-inner" style="width:97px;left:-1px">Seo Wei LEO (Singapore)</div></td><td class="s0">11:26–11:34</td><td class="s1 softmerge"><div class="softmerge-inner" style="width:298px;left:-1px">The Use of Atropine in Real-World Practice</div></td></tr><tr style="height: 20px"><th id="955405797R17" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">18</div></th><td class="s0"></td><td class="s0"></td><td class="s0"></td><td class="s0 softmerge"><div class="softmerge-inner" style="width:97px;left:-1px">Seang Mei SAW (Singapore)</div></td><td class="s0">11:34–11:42</td><td class="s1 softmerge"><div class="softmerge-inner" style="width:298px;left:-1px">Oral Medication: A Novel Pathway</div></td></tr><tr style="height: 20px"><th id="955405797R18" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">19</div></th><td class="s0"></td><td class="s0"></td><td class="s0"></td><td class="s0 softmerge"><div class="softmerge-inner" style="width:97px;left:-1px">Patrick JOHNSON (U.S.)</div></td><td class="s0">11:42–11:50</td><td class="s1 softmerge"><div class="softmerge-inner" style="width:498px;left:-1px">Dilute Atropine: Perspective of a US/European Company’s Investigations</div></td></tr><tr style="height: 20px"><th id="955405797R19" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">20</div></th><td class="s0"></td><td class="s0"></td><td class="s0"></td><td class="s0 softmerge"><div class="softmerge-inner" style="width:97px;left:-1px">Emi INAGAKI (Japan)</div></td><td class="s0">11:50–11:58</td><td class="s1 softmerge"><div class="softmerge-inner" style="width:298px;left:-1px">Regulation of Drugs for Myopia in Japan</div></td></tr><tr style="height: 20px"><th id="955405797R20" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">21</div></th><td class="s0"></td><td class="s0"></td><td class="s0"></td><td class="s0">Bill BOYD (U.S.)</td><td class="s0">11:58–12:06</td><td class="s1 softmerge"><div class="softmerge-inner" style="width:298px;left:-1px">Regulation of Drugs for Myopia in the U.S.</div></td></tr><tr style="height: 20px"><th id="955405797R21" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">22</div></th><td class="s0"></td><td class="s0"></td><td class="s0"></td><td class="s0 softmerge"><div class="softmerge-inner" style="width:97px;left:-1px">Moderators &amp; Panelists</div></td><td class="s0">12:06–12:25</td><td class="s1 softmerge"><div class="softmerge-inner" style="width:198px;left:-1px">Panel Discussion</div></td></tr><tr style="height: 20px"><th id="955405797R22" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">23</div></th><td class="s0 softmerge"><div class="softmerge-inner" style="width:97px;left:-1px">RCSV Lunch Symposium</div></td><td class="s0">12:30–13:30</td><td class="s0">Grand Ballroom</td><td class="s0">-</td><td class="s0">12:30–13:30</td><td class="s1 softmerge"><div class="softmerge-inner" style="width:198px;left:-1px">Lunch Symposium</div></td></tr><tr style="height: 20px"><th id="955405797R23" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">24</div></th><td class="s0 softmerge"><div class="softmerge-inner" style="width:97px;left:-1px">Keynote Lecture 2</div></td><td class="s0">13:30–13:50</td><td class="s0">Grand Ballroom</td><td class="s0 softmerge"><div class="softmerge-inner" style="width:97px;left:-1px">Norbert GORNY (France)</div></td><td class="s0">13:30–13:50</td><td class="s1 softmerge"><div class="softmerge-inner" style="width:598px;left:-1px">Industry’s Role in Expanding the Myopia Toolkit: Catalyzing New Options for a Growing Crisis</div></td></tr><tr style="height: 20px"><th id="955405797R24" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">25</div></th><td class="s0 softmerge"><div class="softmerge-inner" style="width:97px;left:-1px">Session 4: Rays That Slow – Harnessing Light to Fight Myopia</div></td><td class="s0">13:50–14:50</td><td class="s0 softmerge"><div class="softmerge-inner" style="width:97px;left:-1px">Grand III, IV &amp; Annex</div></td><td class="s0 softmerge"><div class="softmerge-inner" style="width:97px;left:-1px">Kazuo TSUBOTA (Japan)</div></td><td class="s0">13:50–13:58</td><td class="s1 softmerge"><div class="softmerge-inner" style="width:398px;left:-1px">Violet Light Hypothesis for Suppression of Myopia</div></td></tr><tr style="height: 20px"><th id="955405797R25" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">26</div></th><td class="s0"></td><td class="s0"></td><td class="s0"></td><td class="s0 softmerge"><div class="softmerge-inner" style="width:97px;left:-1px">Seang Mei SAW (Singapore)</div></td><td class="s0">13:58–14:06</td><td class="s0">TBC</td></tr><tr style="height: 20px"><th id="955405797R26" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">27</div></th><td class="s0"></td><td class="s0"></td><td class="s0"></td><td class="s0 softmerge"><div class="softmerge-inner" style="width:97px;left:-1px">Ian FLITCROFT (Ireland)</div></td><td class="s0">14:06–14:14</td><td class="s1 softmerge"><div class="softmerge-inner" style="width:298px;left:-1px">Blue Light – Evidence for Myopia Management</div></td></tr><tr style="height: 20px"><th id="955405797R27" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">28</div></th><td class="s0"></td><td class="s0"></td><td class="s0"></td><td class="s0 softmerge"><div class="softmerge-inner" style="width:97px;left:-1px">Mingguang HE (Hong Kong)</div></td><td class="s0">14:14–14:22</td><td class="s1 softmerge"><div class="softmerge-inner" style="width:298px;left:-1px">Red Light – Evidence for Myopia Management</div></td></tr><tr style="height: 20px"><th id="955405797R28" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">29</div></th><td class="s0"></td><td class="s0"></td><td class="s0"></td><td class="s0 softmerge"><div class="softmerge-inner" style="width:97px;left:-1px">Don CALOGERO (U.S.)</div></td><td class="s0">14:22–14:30</td><td class="s1 softmerge"><div class="softmerge-inner" style="width:298px;left:-1px">Regulatory Standards for Ocular Light Exposure</div></td></tr><tr style="height: 20px"><th id="955405797R29" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">30</div></th><td class="s0"></td><td class="s0"></td><td class="s0"></td><td class="s0">Panelists</td><td class="s0">14:30–14:50</td><td class="s1 softmerge"><div class="softmerge-inner" style="width:198px;left:-1px">Panel Discussion</div></td></tr><tr style="height: 20px"><th id="955405797R30" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">31</div></th><td class="s0 softmerge"><div class="softmerge-inner" style="width:97px;left:-1px">Session 7: Mapping Myopia – Who, How &amp; How Fast</div></td><td class="s0">13:50–14:50</td><td class="s0 softmerge"><div class="softmerge-inner" style="width:97px;left:-1px">Grand III, IV &amp; Annex</div></td><td class="s0">Kyoko MATSUI</td><td class="s0">13:50–13:58</td><td class="s1 softmerge"><div class="softmerge-inner" style="width:398px;left:-1px">Insights into Prevalence, Progression &amp; Prevention – Japan</div></td></tr><tr style="height: 20px"><th id="955405797R31" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">32</div></th><td class="s0"></td><td class="s0"></td><td class="s0"></td><td class="s0 softmerge"><div class="softmerge-inner" style="width:97px;left:-1px">Tien WONG (China)</div></td><td class="s0">13:58–14:06</td><td class="s1 softmerge"><div class="softmerge-inner" style="width:498px;left:-1px">Insights into Prevalence, Progression &amp; Prevention – Singapore &amp; China</div></td></tr><tr style="height: 20px"><th id="955405797R32" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">33</div></th><td class="s0"></td><td class="s0"></td><td class="s0"></td><td class="s0 softmerge"><div class="softmerge-inner" style="width:97px;left:-1px">David MACKEY / Ian MORGAN</div></td><td class="s0">14:06–14:14</td><td class="s1 softmerge"><div class="softmerge-inner" style="width:398px;left:-1px">Insights into Prevalence, Progression &amp; Prevention – Australia</div></td></tr><tr style="height: 20px"><th id="955405797R33" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">34</div></th><td class="s0"></td><td class="s0"></td><td class="s0"></td><td class="s0 softmerge"><div class="softmerge-inner" style="width:97px;left:-1px">Aude COUTERIER (France)</div></td><td class="s0">14:14–14:22</td><td class="s1 softmerge"><div class="softmerge-inner" style="width:398px;left:-1px">Insights into Prevalence, Progression &amp; Prevention – Europe</div></td></tr><tr style="height: 20px"><th id="955405797R34" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">35</div></th><td class="s0"></td><td class="s0"></td><td class="s0"></td><td class="s0 softmerge"><div class="softmerge-inner" style="width:97px;left:-1px">Jason YAM (Hong Kong)</div></td><td class="s0">14:22–14:30</td><td class="s1 softmerge"><div class="softmerge-inner" style="width:398px;left:-1px">Insights into Prevalence, Progression &amp; Prevention – Hong Kong</div></td></tr><tr style="height: 20px"><th id="955405797R35" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">36</div></th><td class="s0"></td><td class="s0"></td><td class="s0"></td><td class="s0">Panelists</td><td class="s0">14:30–14:50</td><td class="s1 softmerge"><div class="softmerge-inner" style="width:198px;left:-1px">Panel Discussion</div></td></tr><tr style="height: 20px"><th id="955405797R36" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">37</div></th><td class="s0 softmerge"><div class="softmerge-inner" style="width:97px;left:-1px">Session 5: Beyond the Horizon – Radical New Myopia Strategies</div></td><td class="s0">15:20–16:20</td><td class="s0">Grand Ballroom</td><td class="s0 softmerge"><div class="softmerge-inner" style="width:97px;left:-1px">Marcus ANG (Singapore)</div></td><td class="s0">15:20–15:28</td><td class="s1 softmerge"><div class="softmerge-inner" style="width:498px;left:-1px">AI and Digital Tools for Myopia Management for Childhood and Adults</div></td></tr><tr style="height: 20px"><th id="955405797R37" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">38</div></th><td class="s0"></td><td class="s0"></td><td class="s0"></td><td class="s0 softmerge"><div class="softmerge-inner" style="width:97px;left:-1px">Saiko MATSUMURA</div></td><td class="s0">15:28–15:36</td><td class="s1 softmerge"><div class="softmerge-inner" style="width:298px;left:-1px">AI and Digital Tools for Myopia Monitoring</div></td></tr><tr style="height: 20px"><th id="955405797R38" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">39</div></th><td class="s0"></td><td class="s0"></td><td class="s0"></td><td class="s0 softmerge"><div class="softmerge-inner" style="width:97px;left:-1px">Donny HOANG (Singapore)</div></td><td class="s0">15:36–15:44</td><td class="s1 softmerge"><div class="softmerge-inner" style="width:398px;left:-1px">Scleral Cross-Linking for Myopia Control: Where Are We Now?</div></td></tr><tr style="height: 20px"><th id="955405797R39" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">40</div></th><td class="s0"></td><td class="s0"></td><td class="s0"></td><td class="s0 softmerge"><div class="softmerge-inner" style="width:97px;left:-1px">Pei Chang WU (Taiwan)</div></td><td class="s0">15:44–15:52</td><td class="s1 softmerge"><div class="softmerge-inner" style="width:398px;left:-1px">Emerging Myopia Diagnostics and Therapeutics in Taiwan</div></td></tr><tr style="height: 20px"><th id="955405797R40" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">41</div></th><td class="s0"></td><td class="s0"></td><td class="s0"></td><td class="s0 softmerge"><div class="softmerge-inner" style="width:97px;left:-1px">Daniela FERRARA (U.S.)</div></td><td class="s0">15:52–16:00</td><td class="s1 softmerge"><div class="softmerge-inner" style="width:598px;left:-1px">The Need to Establish Population-Based Myopia Data for Prevalence and Progression</div></td></tr><tr style="height: 20px"><th id="955405797R41" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">42</div></th><td class="s0"></td><td class="s0"></td><td class="s0"></td><td class="s0">Panelists</td><td class="s0">16:00–16:20</td><td class="s1 softmerge"><div class="softmerge-inner" style="width:198px;left:-1px">Panel Discussion</div></td></tr><tr style="height: 20px"><th id="955405797R42" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">43</div></th><td class="s0 softmerge"><div class="softmerge-inner" style="width:97px;left:-1px">Session 6: Global Regulatory Pathways for Myopia Control</div></td><td class="s0">16:20–17:55</td><td class="s0">Grand Ballroom</td><td class="s0 softmerge"><div class="softmerge-inner" style="width:97px;left:-1px">Emi INAGAKI (Japan)</div></td><td class="s0">16:20–16:28</td><td class="s1 softmerge"><div class="softmerge-inner" style="width:298px;left:-1px">Japanese Regulatory Perspective</div></td></tr><tr style="height: 20px"><th id="955405797R43" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">44</div></th><td class="s0"></td><td class="s0"></td><td class="s0"></td><td class="s0 softmerge"><div class="softmerge-inner" style="width:97px;left:-1px">Paula Johns (U.S.)</div></td><td class="s0">16:28–16:36</td><td class="s1 softmerge"><div class="softmerge-inner" style="width:198px;left:-1px">U.S. Regulatory Perspective</div></td></tr><tr style="height: 20px"><th id="955405797R44" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">45</div></th><td class="s0"></td><td class="s0"></td><td class="s0"></td><td class="s0">TBC (Singapore)</td><td class="s0">16:36–16:44</td><td class="s1 softmerge"><div class="softmerge-inner" style="width:298px;left:-1px">Singapore Regulatory Perspective</div></td></tr><tr style="height: 20px"><th id="955405797R45" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">46</div></th><td class="s0"></td><td class="s0"></td><td class="s0"></td><td class="s0">TBC (Europe)</td><td class="s0">16:44–16:52</td><td class="s1 softmerge"><div class="softmerge-inner" style="width:298px;left:-1px">European Regulatory Perspective</div></td></tr><tr style="height: 20px"><th id="955405797R46" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">47</div></th><td class="s0"></td><td class="s0"></td><td class="s0"></td><td class="s0">TBC (LMICs)</td><td class="s0">16:52–17:00</td><td class="s1 softmerge"><div class="softmerge-inner" style="width:198px;left:-1px">LMICs Regulatory Considerations</div></td></tr><tr style="height: 20px"><th id="955405797R47" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">48</div></th><td class="s0"></td><td class="s0"></td><td class="s0"></td><td class="s0">TBC (Australia)</td><td class="s0">17:00–17:08</td><td class="s1 softmerge"><div class="softmerge-inner" style="width:298px;left:-1px">Australian Regulatory Perspective</div></td></tr><tr style="height: 20px"><th id="955405797R48" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">49</div></th><td class="s0"></td><td class="s0"></td><td class="s0"></td><td class="s0">TBC (Taiwan)</td><td class="s0">17:08–17:16</td><td class="s1 softmerge"><div class="softmerge-inner" style="width:198px;left:-1px">Taiwan Regulatory Perspective</div></td></tr><tr style="height: 20px"><th id="955405797R49" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">50</div></th><td class="s0"></td><td class="s0"></td><td class="s0"></td><td class="s0">Panelists</td><td class="s0">17:16–17:55</td><td class="s1 softmerge"><div class="softmerge-inner" style="width:198px;left:-1px">Panel Discussion</div></td></tr><tr style="height: 20px"><th id="955405797R50" style="height: 20px;" class="row-headers-background"><div class="row-header-wrapper" style="line-height: 20px">51</div></th><td class="s0">Closing</td><td class="s0">17:55–18:00</td><td class="s0">Grand Ballroom</td><td class="s0 softmerge"><div class="softmerge-inner" style="width:97px;left:-1px">Malvina EYDELMAN (U.S.)</div></td><td class="s0">17:50–18:00</td><td class="s0">Closing Remarks</td></tr></tbody></table></div>